BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 16926353)

  • 1. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
    Kearon C; Ginsberg JS; Julian JA; Douketis J; Solymoss S; Ockelford P; Jackson S; Turpie AG; MacKinnon B; Hirsh J; Gent M;
    JAMA; 2006 Aug; 296(8):935-42. PubMed ID: 16926353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous unfractionated heparin for the treatment of venous thromboembolism.
    Kearon C
    Curr Opin Pulm Med; 2007 Sep; 13(5):398-402. PubMed ID: 17940484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P; Carnovali M; Marchiori A;
    Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
    Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
    Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
    Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
    JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
    van Den Belt AG; Prins MH; Lensing AW; Castro AA; Clark OA; Atallah AN; Burihan E
    Cochrane Database Syst Rev; 2000; (2):CD001100. PubMed ID: 10796593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous unfractionated heparin compared with low-molecular-weight heparin for the initial treatment of venous thromboembolism.
    Bernardi E; Prandoni P
    Curr Opin Pulm Med; 2005 Sep; 11(5):363-7. PubMed ID: 16093806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
    de Valk HW; Banga JD; Wester JW; Brouwer CB; van Hessen MW; Meuwissen OJ; Hart HC; Sixma JJ; Nieuwenhuis HK
    Ann Intern Med; 1995 Jul; 123(1):1-9. PubMed ID: 7539233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
    Couturaud F; Julian JA; Kearon C
    Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
    N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group.
    Hull RD; Raskob GE; Brant RF; Pineo GF; Elliott G; Stein PD; Gottschalk A; Valentine KA; Mah AF
    Arch Intern Med; 2000 Jan; 160(2):229-36. PubMed ID: 10647762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
    Riess H; Koppenhagen K; Tolle A; Kemkes-Matthes B; Gräve M; Patek F; Drexler M; Siemens HJ; Harenberg J; Weidinger G; Brom J; Haas S;
    Thromb Haemost; 2003 Aug; 90(2):252-9. PubMed ID: 12888872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
    Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials.
    Quinlan DJ; McQuillan A; Eikelboom JW
    Ann Intern Med; 2004 Feb; 140(3):175-83. PubMed ID: 14757615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.
    Simonneau G; Sors H; Charbonnier B; Page Y; Laaban JP; Azarian R; Laurent M; Hirsch JL; Ferrari E; Bosson JL; Mottier D; Beau B
    N Engl J Med; 1997 Sep; 337(10):663-9. PubMed ID: 9278462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.
    Chong BH; Brighton TA; Baker RI; Thurlow P; Lee CH;
    J Thromb Thrombolysis; 2005 Jun; 19(3):173-81. PubMed ID: 16082604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.